As leading tobacco companies launch a fresh wave of flavored nicotine tablets in the UK, Switzerland, and the United States, public health advocates are sounding alarms over the potential risks these products pose for young people and the general population.
Philip Morris International has recently introduced Zyn Melts in the United Kingdom and Switzerland, offering a mint-flavored, melt-in-the-mouth tablet that delivers a nicotine hit akin to smoking a cigarette. Similarly, Japan Tobacco International’s Perlz has joined the UK market with comparable qualities. These new entries add to a growing American market, where U.S. startup Nic Nac Naturals has sold its own flavored nicotine lozenges in thousands of retailers since 2022, making such products widely accessible on both sides of the Atlantic.
Concerns Over Youth Appeal and Addiction
The products are creating a rift between tobacco firms—who promote them as harm-reduction alternatives for adult smokers—and public health officials, who warn that their resemblance to everyday mints or lozenges could attract children and adolescents. The American Heart Association, among other organizations, has expressed particular concern that flavored options may perpetuate nicotine addiction and increase the risk of a new generation of youths engaging in regular nicotine use. These warnings are underscored by a steady increase in oral nicotine product use among young people, as observed in ongoing national surveys.
Regulation, Public Opinion, and Scientific Uncertainty
The U.S. Food and Drug Administration has authorized the sale of certain flavored nicotine pouches, arguing that, on balance, their availability offers more benefits than risks, especially for adult smokers looking to quit combustible cigarettes. However, the Centers for Disease Control and Prevention continues to recommend stronger policies to limit access to all tobacco-derived products and shield youth from addiction. Surveys conducted by the CDC indicate that the majority of Americans support stricter regulation or outright bans on tobacco products.
Despite industry claims that nicotine tablets and pouches are meant for adult consumers, the unresolved questions remain critical: There is limited evidence on their effectiveness in helping people quit smoking, and virtually no research on the long-term health consequences of regular use. Some recent studies note the potential for these products to reduce cigarette smoking rates, while others highlight risks of dual use or inconsistent patterns of addiction.
Industry Tactics and Historical Context
This latest product roll-out echoes earlier efforts by tobacco companies to introduce enticingly flavored e-cigarettes and cigars—moves that have previously been linked to increased tobacco uptake among youth. Public health authorities warn that, absent stronger controls, flavored nicotine tablets may follow a similar trajectory.
With their easy availability, unassuming presentation, and ongoing debates around regulation, flavored nicotine tablets remain at the center of an emerging—and highly contested—public health debate. Their ultimate impact on smoking cessation, youth addiction, and long-term disease remains uncertain, and further research is urgently needed.